Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(6):416; doi:10.1093/jnci/94.6.416
© 2002 by Oxford University Press
This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 6, 416, March 20, 2002
© 2002 Oxford University Press

NEWS

Awards, Appointments, Announcements

David G.I. Kingston, Ph.D., has been named Virginia’s Outstanding Scientist of the Year for 2002. Kingston was the first U.S. chemist to study the chemistry of the anticancer drug Taxol. Taxol is now being used to treat breast and ovarian cancer.

Das Appointed

Asha Das, M.D., has been appointed director of the Cedars-Sinai Maxine Dunitz Neurological Institute’s neuro-oncology program. Before joining the Cedars-Sinai Medical Center, Los Angeles, Das was a clinical instructor at the National University of Singapore. Das has also served as a consulting neurologist for Singapore’s National Neuroscience Institute, the National University Hospital, the National Cancer Centre, and Changi General Hospital.

Two Appointed at RPCI

Roswell Park Cancer Institute appointed two new senior vice presidents.

Candace S. Johnson, Ph.D., has been appointed senior vice president for translational research. Johnson was previously deputy director of basic research at the University of Pittsburgh Cancer Institute.

Donald L. Trump, M.D., has been named senior vice president for clinical research, chair of the department of medicine, and co-principal investigator of the Cancer Center Support Grant. Trump was previously deputy director of clinical investigations at the University of Pittsburgh Medical Center.

Vanderbilt Names Two

Two cancer researchers have been appointed to positions at the Vanderbilt-Ingram Cancer Center, Nashville, Tenn.

Jennifer Pietenpol, Ph.D., has been named associate director for basic science programs. She is also an associate professor of biochemistry at Vanderbilt University. Her research focuses on the p53 tumor suppressor gene and the role of cell cycle pathways in cancer.

Scott Hiebert, Ph.D., has been chosen to lead Vanderbilt-Ingram’s program in signal transduction and cell proliferation. Prior to joining the Vanderbilt-Ingram Cancer Center, Hiebert was a member of the Department of Tumor Cell Biology at St. Jude Children’s Research Hospital in Memphis, Tenn. His research focuses on the genetic causes of leukemia.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?